The hearing implant maker is fighting a high-stakes battle against market dark arts and an investor exodus that could trigger ...

When hearing aids are no longer effective, Ryder Boen tries a cochlear implant. As it’s turned on, he’s overwhelmed by what ...

Hearing implant leader MED-EL USA is announcing two upcoming symposia at CI2026, the annual meeting of the American Cochlear Implant Association (ACIA) in Chicago. The meeting also celebrates the ...

The decision to place cochlear implants in both ears at the same time in young children may better shape brain development ...

A major Australian medical company has suffered a $4.4b wipeout after slashing its earnings forecast, which drove its share ...

Cochlear isn’t selling hearing implants like it thought it could or should. It’s been a problem throughout its whole ...

Cochlear’s shares have collapsed after the hearing implants behemoth again downgraded profit guidance by up to $170m on ...

A cochlear implant is a small, complex electronic device that can help to provide a sense of sound to a person who is profoundly deaf or severely hard of hearing. Cochlear implants compensate for ...

After a brutal drop, sentiment has turned negative. But looking beyond the next year, the long-term story may still be intact. The post Down 65%, are Cochlear shares a once-in-a-decade buying ...

MPR spoke with Dr Daniela Carvalho, an investigator in the CHORD trial, the results form which formed the basis for the approval of Otarmeni.

ASX healthcare leaders CSL, Cochlear and Resmed have fallen to multi-year lows, weighing on the sector as earnings downgrades, operational issues and macroeconomic pressures erode sentiment.